BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:39 PM
 | 
Sep 18, 2012
 |  BC Extra  |  Company News

Merck pulls second EU attempt to expand Erbitux for NSCLC

Merck KGaA (Xetra:MRK) withdrew an MAA to extend the label for Erbitux cetuximab to include first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with high EGFR-expression in combination with platinum-based chemotherapy. The pharma said...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >